Coronavirus company news summary – PathoFinder obtains CE Mark for two multiplex SARS-CoV-2 MDx tests – Imanis Life Sciences announces improvements and increased capacity

20 November 2020 (Last Updated November 20th, 2020 10:11)

The Apollo Hospitals Group and Tata Medical and Diagnostics (TataMD) have announced the launch of the TataMD CHECK diagnostic test, reports the Times of India. The test is designed to get quicker test results for Covid-19 in India. It is based on the DNA genome editing tool CRISPR Cas-9, which helps in the quicker delivery of results due to its agile AI-based automated detection procedure.

Cue Health has announced that the US Department of Health and Human Services (HHS) will start deploying its molecular, point-of-care Covid-19 tests across five states: Alaska, Louisiana, Florida, New Jersey and Texas. The tests will be utilised to detect positive and negative cases at nursing homes, assisted living facilities, long-term care, veterans’ homes, and will also be deployed at the Department of Defence.

PathoFinder, a Dutch molecular diagnostics developer, has obtained CE IVD marking for two of its multiplex PCR tests for fighting the SARS-CoV-2 virus and other respiratory pathogens. The firm specifically obtained the CE certification for the RespiFinder 2Smart kit for SARS-CoV-2 and MERS-CoV testing, as well as for the RAQ Flu/Covid-19 PCR kit.

Imanis Life Sciences, a laboratory assays and research services provider, announced that it had completed the validation of its improved IMMUNO-COV assay, in detecting and quantifying SARS-CoV-2 neutralising antibodies. The validation adds plasma as a sample type and improves sensitivity and stability along with high accuracy.